Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 35

1.

Hyper-IgE in the allergy clinic--when is it primary immunodeficiency?

Ponsford MJ, Klocperk A, Pulvirenti F, Dalm VASH, Milota T, Cinetto F, Chovancova Z, Rial MJ, Sediva A, Litzman J, Agostini C, van Hagen M, Quinti I, Jolles S.

Allergy. 2018 Nov;73(11):2122-2136. doi: 10.1111/all.13578. Epub 2018 Oct 2. Review.

PMID:
30043993
2.

Tuberculosis and other causes of uveitis in Indonesia.

La Distia Nora R, Sitompul R, Bakker M, Susiyanti M, Edwar L, Sjamsoe S, Singh G, van Hagen MP, Rothova A.

Eye (Lond). 2018 Mar;32(3):546-554. doi: 10.1038/eye.2017.231. Epub 2017 Nov 3.

3.

The dynamics of early-state transcriptional changes and aggregate formation in a Huntington's disease cell model.

van Hagen M, Piebes DGE, de Leeuw WC, Vuist IM, van Roon-Mom WMC, Moerland PD, Verschure PJ.

BMC Genomics. 2017 May 12;18(1):373. doi: 10.1186/s12864-017-3745-z.

4.

IgG4-related disease as an emerging cause of scleritis.

Karim F, de Hoog J, Paridaens D, Verdijk R, Schreurs M, Rothova A, van Hagen M, van Laar J.

Acta Ophthalmol. 2017 Dec;95(8):e795-e796. doi: 10.1111/aos.13376. Epub 2017 Feb 22. No abstract available.

5.

Genetic defects in PI3Kδ affect B-cell differentiation and maturation leading to hypogammaglobulineamia and recurrent infections.

Wentink M, Dalm V, Lankester AC, van Schouwenburg PA, Schölvinck L, Kalina T, Zachova R, Sediva A, Lambeck A, Pico-Knijnenburg I, van Dongen JJ, Pac M, Bernatowska E, van Hagen M, Driessen G, van der Burg M.

Clin Immunol. 2017 Mar;176:77-86. doi: 10.1016/j.clim.2017.01.004. Epub 2017 Jan 17.

PMID:
28104464
6.

IgG4-related disease: a systematic review of this unrecognized disease in pediatrics.

Karim F, Loeffen J, Bramer W, Westenberg L, Verdijk R, van Hagen M, van Laar J.

Pediatr Rheumatol Online J. 2016 Mar 25;14(1):18. doi: 10.1186/s12969-016-0079-3. Review.

7.

Strategies for B-cell receptor repertoire analysis in primary immunodeficiencies: from severe combined immunodeficiency to common variable immunodeficiency.

IJspeert H, Wentink M, van Zessen D, Driessen GJ, Dalm VA, van Hagen MP, Pico-Knijnenburg I, Simons EJ, van Dongen JJ, Stubbs AP, van der Burg M.

Front Immunol. 2015 Apr 8;6:157. doi: 10.3389/fimmu.2015.00157. eCollection 2015. Review.

8.

Somatostatin analogues for receptor targeted photodynamic therapy.

Kaščáková S, Hofland LJ, De Bruijn HS, Ye Y, Achilefu S, van der Wansem K, van der Ploeg-van den Heuvel A, van Koetsveld PM, Brugts MP, van der Lelij AJ, Sterenborg HJ, Ten Hagen TL, Robinson DJ, van Hagen MP.

PLoS One. 2014 Aug 11;9(8):e104448. doi: 10.1371/journal.pone.0104448. eCollection 2014.

9.

Prevalence of atopic diseases in patients with sarcoidosis.

Hajdarbegovic E, Kamphuis L, van Laar J, van Hagen M, Nijsten T, Thio B.

Allergy Asthma Proc. 2014 Jul-Aug;35(4):e57-61. doi: 10.2500/aap.2014.35.3754.

PMID:
24992543
10.

Clinical manifestations of patients with intraocular inflammation and positive QuantiFERON-TB gold in-tube test in a country nonendemic for tuberculosis.

La Distia Nora R, van Velthoven ME, Ten Dam-van Loon NH, Misotten T, Bakker M, van Hagen MP, Rothova A.

Am J Ophthalmol. 2014 Apr;157(4):754-61. doi: 10.1016/j.ajo.2013.11.013. Epub 2013 Nov 18.

PMID:
24262781
11.

RNF4 and VHL regulate the proteasomal degradation of SUMO-conjugated Hypoxia-Inducible Factor-2alpha.

van Hagen M, Overmeer RM, Abolvardi SS, Vertegaal AC.

Nucleic Acids Res. 2010 Apr;38(6):1922-31. doi: 10.1093/nar/gkp1157. Epub 2009 Dec 21.

12.

Immune-mediated inflammatory diseases: a new multidisciplinary concept.

Baeten D, van Hagen M, Magro F, Filipe P, Fonseca JE.

Acta Reumatol Port. 2009 Jul-Sep;34(3):457-9. No abstract available.

13.

The ubiquitin-proteasome system is a key component of the SUMO-2/3 cycle.

Schimmel J, Larsen KM, Matic I, van Hagen M, Cox J, Mann M, Andersen JS, Vertegaal AC.

Mol Cell Proteomics. 2008 Nov;7(11):2107-22. doi: 10.1074/mcp.M800025-MCP200. Epub 2008 Jun 18.

14.

In vivo identification of human small ubiquitin-like modifier polymerization sites by high accuracy mass spectrometry and an in vitro to in vivo strategy.

Matic I, van Hagen M, Schimmel J, Macek B, Ogg SC, Tatham MH, Hay RT, Lamond AI, Mann M, Vertegaal ACO.

Mol Cell Proteomics. 2008 Jan;7(1):132-44. doi: 10.1074/mcp.M700173-MCP200. Epub 2007 Oct 15.

15.

Polymorphic microsatellite markers for genetic analysis of collagen genes in suspected collagenopathies in dogs.

Temwichitr J, Hazewinkel HA, van Hagen MA, Leegwater PA.

J Vet Med A Physiol Pathol Clin Med. 2007 Nov;54(9):522-6.

PMID:
17931229
16.

Localization of white spotting locus in Boxer dogs on CFA20 by genome-wide linkage analysis with 1500 SNPs.

Leegwater PA, van Hagen MA, van Oost BA.

J Hered. 2007;98(5):549-52. Epub 2007 Jun 4.

PMID:
17548862
17.

Life expectancy in a birth cohort of Boxers followed up from weaning to 10 years of age.

van Hagen MA, Ducro BJ, van den Broek J, Knol BW.

Am J Vet Res. 2005 Sep;66(9):1646-50.

PMID:
16261841
18.

Incidence, risk factors, and heritability estimates of hind limb lameness caused by hip dysplasia in a birth cohort of boxers.

van Hagen MA, Ducro BJ, van den Broek J, Knol BW.

Am J Vet Res. 2005 Feb;66(2):307-12.

PMID:
15757132
19.

Induction of apoptosis with hybrids of Arg-Gly-Asp molecules and peptides and antimitotic effects of hybrids of cytostatic drugs and peptides.

Hofland LJ, Capello A, Krenning EP, de Jong M, van Hagen MP.

J Nucl Med. 2005 Jan;46 Suppl 1:191S-8S. Review.

20.

Analysis of the inheritance of white spotting and the evaluation of KIT and EDNRB as spotting loci in Dutch boxer dogs.

van Hagen MA, van der Kolk J, Barendse MA, Imholz S, Leegwater PA, Knol BW, van Oost BA.

J Hered. 2004 Nov-Dec;95(6):526-31.

PMID:
15475400
21.

Increased cell death after therapy with an Arg-Gly-Asp-linked somatostatin analog.

Capello A, Krenning EP, Bernard BF, Breeman WA, van Hagen MP, de Jong M.

J Nucl Med. 2004 Oct;45(10):1716-20.

22.

Radiolabeled RGD-DTPA-Tyr3-octreotate for receptor-targeted radionuclide therapy.

Bernard B, Capello A, van Hagen M, Breeman W, Srinivasan A, Schmidt M, Erion J, van Gameren A, Krenning E, de Jong M.

Cancer Biother Radiopharm. 2004 Apr;19(2):173-80.

PMID:
15186597
23.

The use of a genetic-counselling program by Dutch breeders for four hereditary health problems in boxer dogs.

van Hagen MA, Janss LL, van den Broek J, Knol BW.

Prev Vet Med. 2004 Apr 30;63(1-2):39-50.

PMID:
15099715
24.

In vivo and in vitro detection of dopamine d2 receptors in uveal melanomas.

Bodei L, Hofland LJ, Ferone D, Mooy CM, Kros JM, Paridaens DA, Baarsma SG, Ferdeghini M, Van Hagen MP, Krenning EP, Kwekkeboom DJ.

Cancer Biother Radiopharm. 2003 Dec;18(6):895-902.

PMID:
14969602
25.

Somatostatin receptors in malignant lymphomas: targets for radiotherapy?

Dalm VA, Hofland LJ, Mooy CM, Waaijers MA, van Koetsveld PM, Langerak AW, Staal FT, van der Lely AJ, Lamberts SW, van Hagen MP.

J Nucl Med. 2004 Jan;45(1):8-16. Erratum in: J Nucl Med. 2005 Feb;46(2):291.

26.

[Genetic and epidemiological investigation in boxers. Cooperation between veterinarians and researchers].

van Hagen MA, van der Gaag I.

Tijdschr Diergeneeskd. 2003 Oct 1;128(19):596-7. Dutch. No abstract available.

PMID:
14582322
27.

[Genetic and epidemiological investigation of a birth cohort of boxers].

Nielen AL, Knol BW, van Hagen MA, van der Gaag I.

Tijdschr Diergeneeskd. 2003 Oct 1;128(19):586-90. Dutch.

PMID:
14582319
28.

Somatostatin receptor subtypes in human thymoma and inhibition of cell proliferation by octreotide in vitro.

Ferone D, van Hagen MP, Kwekkeboom DJ, van Koetsveld PM, Mooy DM, Lichtenauer-Kaligis E, Schönbrunn A, Colao A, Lamberts SW, Hofland LJ.

J Clin Endocrinol Metab. 2000 Apr;85(4):1719-26.

PMID:
10770220
29.

[Horner's syndrome in the dog: a retrospective study].

van Hagen MA, Kwakernaak CM, Boevé MH, Stades FC.

Tijdschr Diergeneeskd. 1999 Oct 15;124(20):600-2. Dutch.

PMID:
10549090
30.

Hepatitis in a patient with SLE: is it autoimmune hepatitis?

Kooy A, de Heide LJ, Engelkens HJ, Mulder AH, van Hagen M, Schalm SW.

Neth J Med. 1996 Apr;48(4):128-32.

PMID:
8999359
31.

How to diagnose autoimmune hepatitis in systemic lupus erythematosus?

Kooy A, de Heide LJ, Engelkens HJ, Mulder AH, van Hagen M, Schalm SW.

Hepatology. 1996 Apr;23(4):936-8. No abstract available.

PMID:
8666353
32.

Somatostatin receptor scintigraphy in the initial staging of Hodgkin's disease.

van den Anker-Lugtenburg PJ, Krenning EP, Oei HY, Van Hagen MP, Gerrits CJ, Reubi JC, Lamberts SW, Löwenberg B.

Br J Haematol. 1996 Apr;93(1):96-103.

PMID:
8611482
33.

Defective maturation and function of antigen-presenting cells in type 1 diabetes.

Jansen A, van Hagen M, Drexhage HA.

Lancet. 1995 Feb 25;345(8948):491-2.

PMID:
7861877
34.

Somatostatin receptor scintigraphy with [111In-DTPA-D-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients.

Krenning EP, Kwekkeboom DJ, Bakker WH, Breeman WA, Kooij PP, Oei HY, van Hagen M, Postema PT, de Jong M, Reubi JC, et al.

Eur J Nucl Med. 1993 Aug;20(8):716-31. Review.

PMID:
8404961
35.

In vitro and in vivo detection of somatostatin receptors in human malignant lymphomas.

Reubi JC, Waser B, van Hagen M, Lamberts SW, Krenning EP, Gebbers JO, Laissue JA.

Int J Cancer. 1992 Apr 1;50(6):895-900.

PMID:
1348240

Supplemental Content

Loading ...
Support Center